コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 rming resurgence in sleeping sickness (human African trypanosomiasis).
2 parenchyma is a major pathogenetic event in African trypanosomiasis.
3 as a promising therapeutic target for human African trypanosomiasis.
4 es as potential novel drug targets for human African trypanosomiasis.
5 Thus, PTR1 may be a drug target for human African trypanosomiasis.
6 development of new treatments against human African trypanosomiasis.
7 treatment and prevention of human and animal African trypanosomiasis.
8 n a highly reproducible mouse model of human African trypanosomiasis.
9 tial target for new compounds to treat human African trypanosomiasis.
10 of four animals in the acute mouse model of African trypanosomiasis.
11 provide variant cross-specific immunity for African trypanosomiasis.
12 inflammatory and regulatory mediators during African trypanosomiasis.
13 undergoing phase III clinical trials against African trypanosomiasis.
14 for inhibitors of therapeutic value against African trypanosomiasis.
15 TAO an important chemotherapeutic target for African trypanosomiasis.
16 keepers to control tsetse flies and, hence, African trypanosomiasis.
17 ated animals in the STIB900 animal model for African trypanosomiasis.
18 ich was developed for the treatment of human African trypanosomiasis.
19 +)-ATPases (PMCAs) of T. brucei, an agent of African trypanosomiasis.
20 teins for developing new serodiagnostics for African trypanosomiasis.
21 antimicrobial peptides for the treatment of African trypanosomiasis.
22 parasite in the Excavate lineage that causes African trypanosomiasis.
23 trypanosomes overcome host resistance during African trypanosomiasis.
24 o showed some in vivo activity in a model of African trypanosomiasis.
25 n-specific Th-cell responses in experimental African trypanosomiasis.
26 discovery process for the treatment of Human African Trypanosomiasis.
27 burden and affecting the loss of fat mass in African trypanosomiasis.
28 itially developed for the treatment of human African trypanosomiasis.
29 gle oral dose cure using acoziborole against African trypanosomiasis.
30 hly specific inhibitors for the treatment of African trypanosomiasis.
31 ei rhodesiense, the causative agent of Human African Trypanosomiasis.
32 ucei, a protozoan parasite that causes human African trypanosomiasis.
33 esiense or T.b. gambiense, which cause human African trypanosomiasis.
34 ainst the trypanosomes responsible for human African trypanosomiasis.
35 asitaemia in a stage 1 animal model of human African trypanosomiasis.
36 eloping treatments for both human and animal African trypanosomiasis.
37 ei is a protozoan parasite that causes human African trypanosomiasis.
38 rypanosoma brucei, the causative parasite of African trypanosomiasis.
39 anosoma brucei, the causative agent of human African trypanosomiasis.
40 ocus on the parasites that cause malaria and African trypanosomiasis.
41 a: Glossinidae), vectors of Human and Animal African trypanosomiasis.
42 of leishmaniasis, Chagas disease, and human African trypanosomiasis.
43 rm the backbone of the pharmacopoeia against African trypanosomiasis.
44 unique compounds for the treatment of human African trypanosomiasis.
45 al therapeutic target for treatment of human African trypanosomiasis.
46 urative in the STIB900 mouse model for human African trypanosomiasis.
47 osoma brucei is the causative agent of human African trypanosomiasis.
48 for the development of drugs to treat human African trypanosomiasis.
49 y as part of a combination therapy for human African trypanosomiasis.
50 c protozoan responsible for human and animal African trypanosomiasis.
51 deration of the wider epidemiology of animal African trypanosomiasis.
52 n Trypanosoma brucei, the causative agent of African trypanosomiasis.
53 mising lead for development of drugs against African trypanosomiasis.
54 potential target for the treatment of human African trypanosomiasis.
55 anosoma brucei, the causative agent of human African trypanosomiasis.
56 egin optimization for the treatment of human African trypanosomiasis.
57 discussed, with a particular focus on human African trypanosomiasis.
58 validated target for the treatment of human African trypanosomiasis.
59 Trypanosoma brucei is the causing agent of African trypanosomiasis.
63 o assess the efficacy of treatment for human African trypanosomiasis, accurate tests that can discrim
64 anosoma brucei, the causative agent of human African trypanosomiasis, affects tens of thousands of su
67 osoma brucei is the causative agent of Human African Trypanosomiasis, also known as sleeping sickness
69 applied serum samples from 85 patients with African trypanosomiasis and 146 control patients who had
70 first-stage or second-stage gambiense human African trypanosomiasis and a cerebrospinal fluid leucoc
71 tes infect a wide host range and cause Human African Trypanosomiasis and Animal African Trypanosomosi
75 dentifies TbCLK1 as a therapeutic target for African trypanosomiasis and establishes a new chemoprote
81 ffolds within the GlaxoSmithKline HAT (Human African Trypanosomiasis) and Chagas chemical boxes, two
82 brucei rhodesiense, a pathogen causing Human African Trypanosomiasis, and a validated drug target.
83 osoma brucei, the protozoan parasite causing African trypanosomiasis, and the tsetse (Glossina) vecto
85 le is Trypanosoma brucei, which causes human African trypanosomiasis, as well as the livestock diseas
87 ted tropical diseases such as leprosy, human African trypanosomiasis, Buruli ulcer, and visceral leis
88 important option for reducing the impact of African trypanosomiasis but, although many effective met
89 lidated as new therapeutic targets for human African trypanosomiasis by both genetic and pharmacologi
90 p novel anti-inflammatory therapies in Human African trypanosomiasis by modulating the NK1 receptor a
91 ral and cutaneous), Chagas disease and human African trypanosomiasis cause substantial death and morb
92 for neglected parasitic diseases, including African trypanosomiasis caused by the protozoan, Trypano
94 re common, particularly in the case of Human African Trypanosomiasis caused by Trypanosoma brucei gam
95 a and comes in two types: East African human African trypanosomiasis caused by Trypanosoma brucei rho
100 , and Leishmania spp., which in humans cause African trypanosomiasis, Chagas disease, and leishmanias
101 e developing world, including malaria, human African trypanosomiasis, Chagas disease, leishmaniasis,
102 um falciparum, the causative agents of human African trypanosomiasis, Chagas disease, leishmaniasis,
105 Trypanosoma brucei, the causative agent of African trypanosomiasis, contains a soluble, vacuolar py
106 the number of reported cases, patients with African trypanosomiasis continue to present major challe
108 iont may also contribute to generating novel African trypanosomiasis disease control strategies.
109 Trypanosoma brucei, the etiological agent of African trypanosomiasis, disease progression can be rapi
110 anosoma brucei, the causative agent of human African trypanosomiasis, encodes a 'classical' La protei
111 ranging pigs in endemic and historical human African trypanosomiasis foci in Guinea and Cote d'Ivoire
115 targeted Trypanosoma brucei gambiense human African trypanosomiasis (gHAT) for elimination as a publ
119 liminate the transmission of gambiense human African trypanosomiasis (gHAT), a vector-borne, parasiti
120 e fatal vector-borne disease gambiense human African trypanosomiasis (gHAT, sleeping sickness) in the
123 e in the pipeline for treatment of CNS human African trypanosomiasis, giving rise to cautious optimis
127 Neglected tropical diseases such as human African trypanosomiasis (HAT) are prevalent primarily in
136 asite Trypanosoma brucei, which causes human African trypanosomiasis (HAT) or sleeping sickness, accu
137 i (T. brucei), the causative agent for human African trypanosomiasis (HAT) or sleeping sickness.
139 is a lead for drug development against human African trypanosomiasis (HAT), a disease caused by Trypa
142 genetically validated drug target for human African trypanosomiasis (HAT), also called African sleep
143 soma brucei, the causative parasite of human African trypanosomiasis (HAT), also known as African sle
146 rtality worldwide; four in particular (human African trypanosomiasis (HAT), Chagas disease, cutaneous
148 brucei, protozoan parasites that cause human African trypanosomiasis (HAT), depend on ornithine uptak
150 lt of their protective effects against human African trypanosomiasis (HAT), or African sleeping sickn
153 rtant drug target for the treatment of human African trypanosomiasis (HAT), raising interest in under
154 Neglected tropical diseases, such as human African trypanosomiasis (HAT), require novel treatments
155 ted immunity, the parasites that cause human African Trypanosomiasis (HAT), Trypanosoma brucei rhodes
156 agnostic serum proteomic signature for human African trypanosomiasis (HAT), using a combination of su
157 represents a promising drug target for human African trypanosomiasis (HAT), which is caused by the pa
158 ist parasite Trypanosoma brucei causes Human African trypanosomiasis (HAT), which threatens millions
170 eroon, a historical focus of gambiense Human African Trypanosomiasis (HAT, sleeping sickness), a dise
172 causative agent of sleeping sickness (Human African Trypanosomiasis, HAT), contains a kinetoplast wi
174 rasitic protozoan and the causative agent of African trypanosomiasis, imports about a thousand protei
175 brucei parasites are the causative agents of African trypanosomiasis in humans, as well as surra, nag
176 w that NTBC could reduce the transmission of African trypanosomiasis in sub-Saharan Africa, thus acce
178 rug will be developed for treatment of human African trypanosomiasis in the near future, increasing a
179 These results implicate both forms of human African trypanosomiasis in the selection and persistence
180 ne), which is used clinically to treat human African trypanosomiasis, inhibits the first step in poly
187 ated molecular target for treatment of human African trypanosomiasis is ornithine decarboxylase (ODC)
189 The treatment of both human and veterinary African trypanosomiasis is still, to a large extent, dep
192 f Trypanosoma brucei, the causative agent of African trypanosomiasis, is characterized by its high ra
195 anosoma brucei, the causative agent of human African trypanosomiasis, led to the identification of su
196 ation, maturation, and Ig class switching in African trypanosomiasis may be partially regulated by un
198 sign of adenosine analogues as drugs against African trypanosomiasis, N(6)-, 2-amino-N(6)-, and N(2)-
200 tity was added to the pharmacopeia for human African trypanosomiasis (or sleeping sickness), orally d
206 gent of the neglected tropical disease human African trypanosomiasis, otherwise known as sleeping sic
207 t Trypanosoma brucei, the causative agent of African trypanosomiasis, possesses a bona fide member of
208 anosoma brucei, the causative agent of human African trypanosomiasis, possesses non-canonical mitocho
209 anosoma brucei, the causative agent of human African trypanosomiasis, possesses two fatty acid synthe
211 mbination therapy for the treatment of human African trypanosomiasis, renewing interest in nitroheter
212 ne models of both early and late stage human African trypanosomiasis, representing a new lead for the
215 es that cause infectious diseases, including African trypanosomiasis (sleeping sickness) in humans an
216 anosoma brucei, the causative agent of Human African Trypanosomiasis (sleeping sickness), yet little
220 ood parasite Trypanosoma brucei causes human African trypanosomiasis ("sleeping sickness") across sub
222 nce to present front line drugs for treating African trypanosomiasis such as melarsoprol (Arsobal) an
224 e critically involved in the pathogenesis of African trypanosomiasis, the contributions to this disea
225 anosoma brucei, the causative agent of human African trypanosomiasis, the NDR kinase, PK50, is expres
226 lthough the situation has improved for human African trypanosomiasis, there remains an urgent need fo
227 f glycolysis in the causative agent of human African trypanosomiasis, Trypanosoma brucei, has already
229 Trypanosoma brucei, the causative agent for African trypanosomiasis undergoes various stages of cell
230 rucei, the pathogen causing Human and Animal African trypanosomiasis, undergoes a complex development
231 ucei, a protozoan parasite that causes human African trypanosomiasis, uses antigenic variation as a m
232 ples obtained from 61 patients in whom human African trypanosomiasis was cured, SL RNA detection had
233 trachoma, visceral leishmaniasis, and human African trypanosomiasis, we used mathematical transmissi
236 ucei is a kinetoplastid parasite that causes African trypanosomiasis, which is fatal if left untreate
237 develop a novel test that can diagnose human African trypanosomiasis with high sensitivity and specif